Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7051112 | 0.99 | TACR1 (0.73) | TACR1 | |
| SCHEMBL6230619 | 0.85 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6230730 | 0.85 | TACR1 (0.73) | TACR1 | |
| SCHEMBL7051150 | 0.85 | TACR1 (0.73) | TACR1 | |
| SCHEMBL6556017 | 0.84 | TACR1 (0.87) | TACR1 | |
| Hydrochloric Acid SCHEMBL7057560 | 0.84 | TACR1 (0.97) | TACR1 | |
| Hydrochloric Acid SCHEMBL7712907 | 0.84 | TACR1 (0.97) | TACR1 | |
| SCHEMBL8090256 | 0.84 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL7706645 | 0.83 | TACR1 (0.70) | TACR1 | |
| Hydrochloric Acid SCHEMBL7706642 | 0.83 | TACR1 (0.70) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010023248-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | HOWARD HARRY R (US) | 2001-09-20 | — | — | US | claimed |
| EP-0675886-B1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0769300-A2 | Antiemetic composition containing an NK-1 receptor antagonists | PFIZER INC. (US) | 1997-04-23 | — | — | EP | claimed |
| EP-0675886-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-10-11 | — | — | EP | claimed |
| WO-1994013663-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | claimed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1515708-A1 | COMBINATIONS OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | Pfizer Products Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040220274-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| EP-0721778-B1 | NK-1 receptor antagonists for the treatment of neuronal injury and stroke | PFIZER (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-20040001895-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-0659409-A2 | Substance 1 antagonists for the inhibition of angiogenesis | PFIZER INC. (US) | 1995-06-28 | — | — | EP | disclosed |
| EP-0655246-A1 | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria | PFIZER INC. (US) | 1995-05-31 | — | — | EP | disclosed |
| EP-0653208-A2 | Pharmaceutical agents for treatment or prevention of sunburn | PFIZER INC. (US) | 1995-05-17 | — | — | EP | disclosed |
| US-5393762-A | Pharmaceutical agents for treatment of emesis | PFIZER INC. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0627221-A2 | Substance P antagonists for the treatment of emesis | PFIZER INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5340826-A | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-23 | — | — | US | disclosed |
| EP-0610021-A1 | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-10 | — | — | EP | disclosed |
| WO-1994013663-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TACR1 1/4885 |
| US-20010023248-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | NPY1R, OPRK1, OPRL1 | TACR1 5/4885 |
| US-20040001895-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885 |
| US-20040220274-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.